flow trial semaglutide nejm The Big of a GLP-1 drug (Wegovy) to Reduce Major Cardiovascular Events Semaglutide in patients with overweight

GLP-1 receptor agonists reduce all-cause mortality and major adverse cardiovascular events (MACE) by approximately 1213% in high-risk populations, as detailed in this 2025 review of cardiovascular effects of GLP-1 receptor agonists on PubMed

These data are fed into an algorithm that measures thousands of firms against each other

Kim KA, Park PW, Kim HK, et al

Sporadic use, taking it some days and skipping others, undermines the microbiome-remodeling mechanism that represents the primary long-term benefit of the product

The best way to find out if this treatment is right for you is to consult with a healthcare provider who knows your health history and could help you weigh the pros and cons

Post-marketing surveillance will help to elucidate whether the subcutaneous and oral variant differ in their real-world safety profile